What does ODRP Pharma do?

ODRP Pharma is a logistics company in Gent. Private Limited, started on 23 January 1998, 1 establishment.

What is the address of ODRP Pharma?

The registered office of ODRP Pharma is located at Oostakkerdorp 26, 9041 Gent.

Is ODRP Pharma still active?

Yes. According to the CBE (29 October 2026) ODRP Pharma is active, legal situation “Normale toestand”, started on 23 January 1998.

Is ODRP Pharma registered on Peppol?

Yes, ODRP Pharma is registered on the Peppol network with ID 0208:0462507084.

What is the enterprise number of ODRP Pharma?

The enterprise number of ODRP Pharma is BE0462507084.

When was ODRP Pharma founded?

ODRP Pharma was founded on 23 January 1998.

Who are the directors of ODRP Pharma?

According to the 2025 annual accounts, the directors of ODRP Pharma are: Sodiap BV, Alexo BV.

Is ODRP Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 January 1998; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did ODRP Pharma make in 2025?

ODRP Pharma posted a profit after taxes of € 70,773 in financial year 2025.

What is the revenue of ODRP Pharma?

As a small company, ODRP Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 194,971.

How much does an employee at ODRP Pharma earn?

The average wage cost per full-time employee at ODRP Pharma was € 114,200 in 2025: staff costs of € 114,224 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ODRP Pharma have?

According to the 2025 annual accounts, ODRP Pharma has 1 full-time equivalents (FTE).

ODRP Pharma (Private Limited) - Gent - BE0462507084

Dossier ODRP Pharma, printed on 29 October 2026 from databakkes.be/en/0462507084/odrp-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ODRP Pharma from Gent, company number BE0462507084, closed financial year 2025 with a result of € 70,773 after tax. For that financial year ODRP Pharma recorded a gross margin of € 194,971 and equity of € 2 million. Compared with financial year 2024, the result moved from € 72,635 to € 70,773. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Growing

€ 2 million

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 70,773

▼ 3% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 22,806

▼ 5% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.5 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 114,224

▲ 2% vs 2024

€ 114,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,340

▲ 37% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 252,857

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,817

▲ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 259,899 Gross margin 2022: € 259,899 First fiscal year in the series	€ 179,726 Gross margin 2023: € 179,726 ▼ 31% vs 2022 (€ 259,899) Unfavourable step	€ 175,813 Gross margin 2024: € 175,813 ▼ 2% vs 2023 (€ 179,726) Unfavourable step	€ 194,971 Gross margin 2025: € 194,971 ▲ 11% vs 2024 (€ 175,813) Favourable step	▲ 11%
Profit after taxes	€ 132,422 Profit after taxes 2022: € 132,422 First fiscal year in the series	€ 82,118 Profit after taxes 2023: € 82,118 ▼ 38% vs 2022 (€ 132,422) Unfavourable step	€ 72,635 Profit after taxes 2024: € 72,635 ▼ 12% vs 2023 (€ 82,118) Unfavourable step	€ 70,773 Profit after taxes 2025: € 70,773 ▼ 3% vs 2024 (€ 72,635) Unfavourable step	▼ 3%
Equity	€ 3,168,392 Equity 2022: € 3,168,392 First fiscal year in the series	€ 1,825,510 Equity 2023: € 1,825,510 ▼ 42% vs 2022 (€ 3,168,392) Unfavourable step	€ 1,898,145 Equity 2024: € 1,898,145 ▲ 4% vs 2023 (€ 1,825,510) Favourable step	€ 1,968,918 Equity 2025: € 1,968,918 ▲ 4% vs 2024 (€ 1,898,145) Favourable step	▲ 4%
Total debts	€ 179,200 Total debts 2022: € 179,200 First fiscal year in the series	€ 282,434 Total debts 2023: € 282,434 ▲ 58% vs 2022 (€ 179,200) Unfavourable step	€ 271,059 Total debts 2024: € 271,059 ▼ 4% vs 2023 (€ 282,434) Favourable step	€ 275,674 Total debts 2025: € 275,674 ▲ 2% vs 2024 (€ 271,059) Unfavourable step	▲ 2%
Cash	€ 12,090 Cash 2022: € 12,090 First fiscal year in the series	€ 20,970 Cash 2023: € 20,970 ▲ 73% vs 2022 (€ 12,090) Favourable step	€ 23,942 Cash 2024: € 23,942 ▲ 14% vs 2023 (€ 20,970) Favourable step	€ 22,806 Cash 2025: € 22,806 ▼ 5% vs 2024 (€ 23,942) Unfavourable step	▼ 5%
Land & buildings	€ 345,474 Land & buildings 2022: € 345,474 First fiscal year in the series	€ 326,450 Land & buildings 2023: € 326,450 ▼ 6% vs 2022 (€ 345,474) Unchanged	€ 307,426 Land & buildings 2024: € 307,426 ▼ 6% vs 2023 (€ 326,450) Unchanged	€ 288,401 Land & buildings 2025: € 288,401 ▼ 6% vs 2024 (€ 307,426) Unchanged	▼ 6%
Retained profit	€ 2,686,686 Retained profit 2022: € 2,686,686 First fiscal year in the series	€ 1,343,805 Retained profit 2023: € 1,343,805 ▼ 50% vs 2022 (€ 2,686,686) Unfavourable step	€ 1,416,439 Retained profit 2024: € 1,416,439 ▲ 5% vs 2023 (€ 1,343,805) Favourable step	€ 1,487,213 Retained profit 2025: € 1,487,213 ▲ 5% vs 2024 (€ 1,416,439) Favourable step	▲ 5%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 1,425,000 Dividend 2023: € 1,425,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 1,425,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 3,347,592 Balance sheet total 2022: € 3,347,592 First fiscal year in the series	€ 2,107,944 Balance sheet total 2023: € 2,107,944 ▼ 37% vs 2022 (€ 3,347,592) Unchanged	€ 2,169,203 Balance sheet total 2024: € 2,169,203 ▲ 3% vs 2023 (€ 2,107,944) Unchanged	€ 2,244,592 Balance sheet total 2025: € 2,244,592 ▲ 3% vs 2024 (€ 2,169,203) Unchanged	▲ 3%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1 Employees (FTE) 2023: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of ODRP Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ODRP Pharma?

What happened at ODRP Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: profit of € 70,773 (▼ 3% vs 2024). Source: NBB ↗
2022 Alexo BV became a director. NBB
2020 Sodiap BV became a director. NBB
Mar 25, 1998 New establishment in Gent. KBO
Jan 23, 1998 Start of the company according to the CBE. KBO

In short

From € 132,422 profit in 2022 to € 70,773 profit in 2025.

Paid € 122,938 in corporate taxes since 2022.

Best year ever: 2022, with € 132,422 profit.

On average € 195,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ODRP Pharma

Behind ODRP Pharma are Sodiap BV and Alexo BV. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap BV

Managing director · represented by Tom Goderis

Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more

since 2020

Alexo BV

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Oostakkerdorp 26

9041 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0462.507.084

VAT number

BE 0462.507.084

Registered office

Oostakkerdorp 26, 9041 Gent

Names & denominations

ODRP Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 January 1998

Peppol

Active · Active since 6 Jun 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

ODRP Pharma

Financials

What happened to ODRP Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions